Xue, Xuemin
Huang, Wenting
Qiu, Tian
Guo, Lei
Ying, Jianming http://orcid.org/0000-0002-7301-4118
Lv, Ning
Funding for this research was provided by:
the Capital Clinical Characteristic Application Research (Z151100004015121)
Beijing Hope Run Special Fund (LC2018B10, LC2014L13)
PUMC Youth Fund and the Fundamental Research Funds for the Central Universities (3332016026)
CAMS Innovation Fund for Medical Sciences (2016-I2M-1-001)
Article History
Received: 11 March 2020
Accepted: 11 August 2020
First Online: 27 August 2020
Ethics approval and consent to participate
: This is a retrospective study that was launched in November 2014. The cases enrolled in this project were diagnosed between Jan 2009 and Oct 2010, whose FFPE samples were used. The data regarding treatment and prognosis were acquired by means of medical record consultation and telephone conversation. Thus, the need for consent was waived by the Independent Ethics Committee of Cancer Hospital, Chinese Academy of Medical Sciences, National GCP Center for Anticancer Drugs (NCC2015ST-05).
: Not applicable.
: The authors declare that they have no competing interests.